With the new licence, generic manufacturers and other companies based anywhere in the world can develop, manufacture and sell low cost, paediatric versions of raltegravir in countries where 98 percent of children with HIV in the developing world live.
6 patent holders, 10 generic manufacturing partners, 12 ARVs to benefit countries home to 87-93% of people living with HIV in the developing world
The Medicines Patent Pool Signs Licensing Agreement with AbbVie for HIV Paediatric Formulations of Lopinavir and Ritonavir
The Medicines Patent Pool (MPP) was created to increase access to quality, appropriate, affordable medicines for people living with HIV in developing countries.
In May 2014 UNITAID, DNDi and MPP launched the PHTI to improve the lives of children living with HIV.
The Medicines Patent Pool is a United Nations-backed organisation established in 2010 to improve access to appropriate, affordable HIV
medicines and technologies for people living with HIV in developing countries. Learn more.
Priority Antiretrovirals for the Medicines Patent Pool
The Patent Status Database for HIV Medicines
Recent Statements from the Executive Director
11 June 2015
9 June 2015
20 May 2015
11 May 2015
8 May 2015
How to convince big pharma to share intellectual property to improve global health
The MPP by the numbers and more
Multilingual WordPress by ICanLocalize